Neotribe Ventures announces the successful IPO of portfolio company BillionToOne, a leader in precision diagnostics, marking a major milestone for the company and its mission to expand access to advanced molecular testing.
MENLO PARK, Calif., Nov. 6, 2025 /PRNewswire-PRWeb/ -- Neotribe Ventures, a venture capital firm that backs bold founders building breakthrough technologies that reimagine what's possible, today celebrated a major milestone for portfolio company BillionToOne, which has completed its initial public offering (IPO), on NASDAQ under the ticker BLLN.
BillionToOne's IPO marks a significant step forward in its mission to make precision diagnostics more accessible and affordable for patients and clinicians around the world. The company is the creator of UNITY Complete®, the first-and-only clinically validated, non-invasive prenatal test that provides a direct fetal risk assessment for up to 14 recessive and X-linked genes, aneuploidies, and more all from a single maternal blood sample. BillionToOne has since expanded its diagnostic platform into oncology with its Northstar Select® and Northstar Response® tests, reflecting its vision to democratize access to precision diagnostics at scale.
"From the moment we met Oghuzan and the BillionToOne team, we knew they were building something extraordinary," said Kittu Kolluri, Founder and Managing Director at Neotribe Ventures. "They've combined scientific rigor with an unwavering commitment to patient impact, a combination that's exceedingly rare and deeply inspiring to back. This IPO represents not just a financial milestone, but a validation of their bold vision and relentless execution."
Neotribe Ventures first invested in BillionToOne's Series A through its flagship Fund I and subsequently increased its commitment with a super pro-rata investment in the company's Series B via the firm's Ignite Fund. Co-managed by Founder and Managing Director Kolluri and Partner Rebecca Mitchem, Ignite supports growth-stage companies developing breakthrough technologies across sectors including computational biology, healthcare, enterprise software, and clean energy.
Neotribe Ventures invests in early- to growth-stage companies developing breakthrough technologies across enterprise software, AI/ML, security, software infrastructure, computational biology, and robotics, among others. The firm takes a hands-on, founder-first approach, supporting nearly 50 companies across the U.S., Europe, Israel, India, and Australia, including BillionToOne, Auditoria, Stand, and Theta Lake, as they transform bold ideas into enduring businesses.
To learn more, visit www.neotribe.vc and www.billiontoone.com.
About Neotribe Ventures
Neotribe Ventures backs bold founders building breakthrough technologies that reimagine what's possible. Founded in 2017 by longtime NEA General Partner Kittu Kolluri, an early investor in dozens of category-defining companies including Box, Robinhood, Scopely, and Climate Corporation, Neotribe manages over $480 million across multiple funds. The firm invests in early- to growth-stage companies across enterprise software, AI/ML, security, software infrastructure, robotics, climate tech, and computational biology. True to its name, Neotribe believes startups thrive when they are supported by a trusted tribe—partners who offer the security, confidence, and guidance to pursue ambitious ideas and lasting impact.
Learn more at www.neotribe.vc.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more powerful, accurate, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT™) technology, is the only multiplex methodology that can accurately count DNA molecules at the single-molecule level.
For more information, please visit www.billiontoone.com.
Media Contact
Kristin Ostro, Neotribe, 1 6193020058, [email protected], Neotribe.vc
SOURCE Neotribe
Share this article